Last updated 4 months ago

Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens

176 patients around the world

Available in Brazil

Beneficência Portuguesa de São Paulo

1Research sites

176Patients around the world

Requirements for the patient

From 18 Years

All Gender

: Individuals who present with the onset of febrile neutropenia and at the same time present colonization with an ESBL-producing pathogen (identified through positive routine rectal swabs and/or positive culture of clinical specimen) or risk of infection with an ESBL-producing pathogen (use of 3rd/4th gen cephalosporin or piperacillin/tazobactam for at least 48 hours in the last 30 days).

: Patients known to be colonized with carbapenem-resistant or CEF/TAZ-resistant pathogens
Patients with previous use of carbapenems for at least 48h in the past 30 days are also excluded due to risk of resistance to the study drugs.
Growth of a pathogen resistant to either study drug in a relevant clinical specimen during the intervention phase will be followed by adjustment of therapy according to local protocol, unblinding, and exclusion from the study.
Patients that have received less than 72h of either study drug will also be excluded from the final analyses.

A Beneficência Portuguesa de São Paulo

São Paulo

StudyCLEMENT

SponsorBeneficência Portuguesa de São Paulo

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT06342115